4Barchiesi F, Cogliati M, Esposto MC, et al. Comparative analysis of pathogenicity of Cryptoeoecus neoformans serotypes A, D and AD in murine cryptococcosis. J Infect,2005,51:10-16.
5Hajjeh RA, Conn LA, Stephens DS, et al. Cryptococcosis: populationbased multistate active surveillance and risk factors in human immunodeficiency virus-infected persons. Cryptoeoccal Active Surveillance Group. J Infect Dis, 1999,179:449-454.
6Currie BP, Casadevall A. Estimation of the prevalence of cryptececcal infection among patients infected with the human immunodeficiency virus in New York City. Clin Infect Dis, 1994,19:1029-1033.
7Mirza SA,Phelan M,Rimland D,et al. The changing epidemiology of cryptoeoecosis :an update from population-based active surveillance in 2 large metropolitan areas, 1992-2000. Clin Infect Dis,2003,36:789-794.
8Campbell GD. Primary pulmonary cryptococcosis. Am Rev Respir Dis, 1966,94:236-243.
9Saag MS,Graybill RJ,Larsen RA, et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin Infect Dis ,2000,30:710-718.
10Vilchez RA,Irish W,Lacomis J,et al. The clinical epidemiology of pulmonary cryptococcosis in non-AIDS patients at a tertiary care medical center. Medicine (Baltimore),2001,80:308-312.
